Logo image of CTEV

CLARITEV CORP (CTEV) Stock Fundamental Analysis

NYSE:CTEV - New York Stock Exchange, Inc. - US62548M2098 - Common Stock - Currency: USD

26.86  +1.83 (+7.31%)

After market: 26.86 0 (0%)

Fundamental Rating

2

Overall CTEV gets a fundamental rating of 2 out of 10. We evaluated CTEV against 37 industry peers in the Health Care Technology industry. Both the profitability and financial health of CTEV have multiple concerns. CTEV has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year CTEV has reported negative net income.
CTEV had a positive operating cash flow in the past year.
CTEV had negative earnings in 4 of the past 5 years.
CTEV had a positive operating cash flow in each of the past 5 years.
CTEV Yearly Net Income VS EBIT VS OCF VS FCFCTEV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -500M -1B -1.5B

1.2 Ratios

With a Return On Assets value of -31.95%, CTEV is not doing good in the industry: 64.86% of the companies in the same industry are doing better.
CTEV has a worse Return On Equity (-1958.81%) than 78.38% of its industry peers.
Looking at the Return On Invested Capital, with a value of 1.58%, CTEV belongs to the top of the industry, outperforming 81.08% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for CTEV is below the industry average of 6.64%.
Industry RankSector Rank
ROA -31.95%
ROE -1958.81%
ROIC 1.58%
ROA(3y)-13.68%
ROA(5y)-9.22%
ROE(3y)-665.39%
ROE(5y)-402.43%
ROIC(3y)2.41%
ROIC(5y)N/A
CTEV Yearly ROA, ROE, ROICCTEV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

CTEV has a better Operating Margin (10.63%) than 91.89% of its industry peers.
In the last couple of years the Operating Margin of CTEV has declined.
Looking at the Gross Margin, with a value of 74.27%, CTEV is in the better half of the industry, outperforming 78.38% of the companies in the same industry.
CTEV's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 10.63%
PM (TTM) N/A
GM 74.27%
OM growth 3Y-33.57%
OM growth 5Y-22.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.14%
GM growth 5Y-2.61%
CTEV Yearly Profit, Operating, Gross MarginsCTEV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

1

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so CTEV is destroying value.
Compared to 1 year ago, CTEV has about the same amount of shares outstanding.
CTEV has less shares outstanding than it did 5 years ago.
CTEV has a worse debt/assets ratio than last year.
CTEV Yearly Shares OutstandingCTEV Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 200M 400M 600M
CTEV Yearly Total Debt VS Total AssetsCTEV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.2 Solvency

Based on the Altman-Z score of -0.30, we must say that CTEV is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -0.30, CTEV perfoms like the industry average, outperforming 45.95% of the companies in the same industry.
A Debt/Equity ratio of 53.67 is on the high side and indicates that CTEV has dependencies on debt financing.
CTEV's Debt to Equity ratio of 53.67 is on the low side compared to the rest of the industry. CTEV is outperformed by 78.38% of its industry peers.
Industry RankSector Rank
Debt/Equity 53.67
Debt/FCF N/A
Altman-Z -0.3
ROIC/WACC0.25
WACC6.44%
CTEV Yearly LT Debt VS Equity VS FCFCTEV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B 5B

2.3 Liquidity

CTEV has a Current Ratio of 0.82. This is a bad value and indicates that CTEV is not financially healthy enough and could expect problems in meeting its short term obligations.
CTEV has a Current ratio of 0.82. This is in the lower half of the industry: CTEV underperforms 64.86% of its industry peers.
A Quick Ratio of 0.82 indicates that CTEV may have some problems paying its short term obligations.
CTEV has a Quick ratio of 0.82. This is in the lower half of the industry: CTEV underperforms 64.86% of its industry peers.
Industry RankSector Rank
Current Ratio 0.82
Quick Ratio 0.82
CTEV Yearly Current Assets VS Current LiabilitesCTEV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for CTEV have decreased strongly by -897.50% in the last year.
The Revenue has decreased by -3.21% in the past year.
The Revenue has been decreasing by -1.09% on average over the past years.
EPS 1Y (TTM)-897.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-185.83%
Revenue 1Y (TTM)-3.21%
Revenue growth 3Y-5.92%
Revenue growth 5Y-1.09%
Sales Q2Q%-1.36%

3.2 Future

CTEV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.99% yearly.
Based on estimates for the next years, CTEV will show a small growth in Revenue. The Revenue will grow by 2.81% on average per year.
EPS Next Y85.54%
EPS Next 2Y35.79%
EPS Next 3Y21.99%
EPS Next 5YN/A
Revenue Next Year-0.06%
Revenue Next 2Y1.48%
Revenue Next 3Y2.81%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CTEV Yearly Revenue VS EstimatesCTEV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M 1B
CTEV Yearly EPS VS EstimatesCTEV Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 0 -20 -40 -60 -80

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CTEV. In the last year negative earnings were reported.
Also next year CTEV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CTEV Price Earnings VS Forward Price EarningsCTEV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

94.59% of the companies in the same industry are more expensive than CTEV, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 9.27
CTEV Per share dataCTEV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -100 -200

4.3 Compensation for Growth

A more expensive valuation may be justified as CTEV's earnings are expected to grow with 21.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.79%
EPS Next 3Y21.99%

More info and screens

0

5. Dividend

5.1 Amount

CTEV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLARITEV CORP

NYSE:CTEV (5/14/2025, 8:04:01 PM)

After market: 26.86 0 (0%)

26.86

+1.83 (+7.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)07-30 2025-07-30
Inst Owners47.86%
Inst Owner ChangeN/A
Ins Owners6%
Ins Owner Change26.32%
Market Cap449.37M
Analysts77.78
Price Target22.1 (-17.72%)
Short Float %3.89%
Short Ratio4.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-29.46%
Min EPS beat(2)-73.58%
Max EPS beat(2)14.65%
EPS beat(4)2
Avg EPS beat(4)-370.31%
Min EPS beat(4)-1467.36%
Max EPS beat(4)45.02%
EPS beat(8)5
Avg EPS beat(8)-168.93%
EPS beat(12)6
Avg EPS beat(12)-282.74%
EPS beat(16)9
Avg EPS beat(16)-181.58%
Revenue beat(2)0
Avg Revenue beat(2)-3.09%
Min Revenue beat(2)-3.29%
Max Revenue beat(2)-2.88%
Revenue beat(4)0
Avg Revenue beat(4)-4.72%
Min Revenue beat(4)-6.88%
Max Revenue beat(4)-2.88%
Revenue beat(8)2
Avg Revenue beat(8)-2.62%
Revenue beat(12)3
Avg Revenue beat(12)-3.01%
Revenue beat(16)6
Avg Revenue beat(16)-1.99%
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.48
P/FCF N/A
P/OCF 4.18
P/B 5.35
P/tB N/A
EV/EBITDA 9.27
EPS(TTM)-71.82
EYN/A
EPS(NY)-10.87
Fwd EYN/A
FCF(TTM)-0.63
FCFYN/A
OCF(TTM)6.43
OCFY23.95%
SpS55.63
BVpS5.02
TBVpS-271.69
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.95%
ROE -1958.81%
ROCE 2%
ROIC 1.58%
ROICexc 1.59%
ROICexgc 26.88%
OM 10.63%
PM (TTM) N/A
GM 74.27%
FCFM N/A
ROA(3y)-13.68%
ROA(5y)-9.22%
ROE(3y)-665.39%
ROE(5y)-402.43%
ROIC(3y)2.41%
ROIC(5y)N/A
ROICexc(3y)2.48%
ROICexc(5y)N/A
ROICexgc(3y)66.67%
ROICexgc(5y)N/A
ROCE(3y)3.05%
ROCE(5y)N/A
ROICexcg growth 3Y-40.96%
ROICexcg growth 5Y-27.14%
ROICexc growth 3Y-26.84%
ROICexc growth 5Y-14.89%
OM growth 3Y-33.57%
OM growth 5Y-22.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.14%
GM growth 5Y-2.61%
F-Score4
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 53.67
Debt/FCF N/A
Debt/EBITDA 8.49
Cap/Depr 27.34%
Cap/Sales 12.69%
Interest Coverage 0.31
Cash Conversion 20.27%
Profit Quality N/A
Current Ratio 0.82
Quick Ratio 0.82
Altman-Z -0.3
F-Score4
WACC6.44%
ROIC/WACC0.25
Cap/Depr(3y)25.06%
Cap/Depr(5y)22.79%
Cap/Sales(3y)10.77%
Cap/Sales(5y)9.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-897.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-185.83%
EPS Next Y85.54%
EPS Next 2Y35.79%
EPS Next 3Y21.99%
EPS Next 5YN/A
Revenue 1Y (TTM)-3.21%
Revenue growth 3Y-5.92%
Revenue growth 5Y-1.09%
Sales Q2Q%-1.36%
Revenue Next Year-0.06%
Revenue Next 2Y1.48%
Revenue Next 3Y2.81%
Revenue Next 5YN/A
EBIT growth 1Y-41.76%
EBIT growth 3Y-37.5%
EBIT growth 5Y-23.25%
EBIT Next Year144.27%
EBIT Next 3Y35.47%
EBIT Next 5YN/A
FCF growth 1Y-116.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.33%
OCF growth 3Y-35.69%
OCF growth 5Y-17.66%